Search Results

ProJenX, Inc. announced the receipt of a $1M Hoffman ALS Clinical Trials Award from the ALS Association.

The ALS Association, the leading national non-profit organization dedicated to fighting ALS on every front, is excited to announce its inaugural ALS Nexus Conference, taking place July 14-17, 2024 at The Gaylord Texan Resort & Conference Center in Grapevine, Texas.

Coave Therapeutics is delighted to announce that it is one of six organisations sharing $2.9 million in grants from the ALS Association that support the advancement of novel therapies for the treatment of amyotrophic lateral sclerosis.

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator.

The ALS Association proudly announces the largest single gift in its history from the estate of the late philanthropist Hugh Hoffman.

Myrobalan Therapeutics is honored to announce a $400,000 grant from the ALS Association to support the advancement of its colony-stimulating factor-1 receptor (CSF1R) inhibitor for the treatment of amyotrophic lateral sclerosis (ALS).

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced it has been honored with an invitation to apply for a prestigious grant from the ALS Association head by James Berry, MD, MPH and Suma Babu, MBBS, MS, the Director and Co-Director of the Neurological Clinical Research Institute (NCRI) at Mass General Hospital, a founding member of Mass General Brigham.

Dewpoint Therapeutics Inc. announced that it was awarded a Target ALS Foundation grant, in collaboration with the ALS Association and The Jackson Laboratory, for an in vivo proof-of-concept study of c-mods in a chronic C9orf72 repeat, the most common genetic cause of ALS.